74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Delabaye, Isabelle ^a   De Keyser, Filip ^b  

^a Schering Plough nv ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BENIGN TUMOR; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYANOSIS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; INJURY; LIVER TOXICITY; LUNG CANCER; LUNG EMBOLISM; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MOUTH EDEMA; MULTICENTER STUDY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PERIPHERAL EDEMA; PREDICTOR VARIABLE; PREVALENCE; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN ALLERGY; SKIN DISEASE; SYNCOPE; TACHYCARDIA; THROAT DISEASE; TUBERCULOUS MENINGITIS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS MENINGITIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; HEALTH SURVEY; LONGITUDINAL STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953667768     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3058     Document Type: Article

References (41)

1. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology 2009, 83:1-9. 10.1159/000165777, 18957873.
2. Roberts LJ, Cleland LG, Thomas R, Proudman SM. Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. Med J Aust 2006, 184:122-125.
3. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009, 11(Suppl 1):S1. 10.1186/ar2666, 2669237, 19368701.
4. Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008, 66:173-178. 10.1111/j.1365-2125.2008.03222.x, 2492934, 18537958.
5. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006, 58:473-492.
6. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545. 10.1172/JCI36389, 2575731, 18982160.
7. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghraveb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30:1443-1453. 10.1016/0161-5890(93)90106-L, 8232330.
8. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166.
9. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0, 10622295.
10. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35. 10.1002/art.20712, 15641102.
11. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086. 10.1002/art.21734, 16572442.
12. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:1462-1466. 10.1136/ard.2007.070771, 2111638, 17502359.
13. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
14. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158. 10.1002/art.10679, 12483718.
15. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751. 10.1002/art.20311, 15188349.
16. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68:1136-1145. 10.1136/ard.2008.091025, 18753157.
17. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439. 10.1002/art.22579, 17469100.
18. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68:648-653. 10.1136/ard.2007.085852, 18467516.
19. Bertoli AM, Strusberg I, Baravalle M, Betelu Z, Calas D, Morales L, Strusberg AM. Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice. J Clin Rheumatol 2008, 14:313-317. 10.1097/RHU.0b013e31817a7e0e, 18690164.
20. Figueiredo IT, Morel J, Sany J, Combe B. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. Clin Exp Rheumatol 2008, 26:18-23.
21. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005, 72:309-312. 10.1016/j.jbspin.2004.08.008, 16038842.
22. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
23. Scott DL, Houssien DA. Joint assessment in rheumatoid arthritis. Br J Rheumatol 1996, 35(Suppl 2):14-18.
24. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000, 14(Suppl C):29C-32C.
25. Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) 2005, 44:472-478. 10.1093/rheumatology/keh508, 15598707.
26. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103. 10.1136/ard.2007.080002, 2564802, 18055472.
27. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1339-1344. 10.1136/ard.2006.062760, 1994293, 17261532.
28. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189-194. 10.1136/ard.2007.072967, 17644554.
29. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127. 10.1002/art.11137, 12905464.
30. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 27:19-30. 10.1111/j.1365-2036.2007.03553.x, 17944997.
31. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568. 10.1002/art.24463, 19405000.
32. Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006, 8:R131. 10.1186/ar2020, 1779374, 16869978.
33. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305-311. 10.1016/j.amjmed.2003.09.039, 14984815.
34. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
35. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58:667-677. 10.1002/art.23281, 18311816.
36. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005, 64:1274-1279. 10.1136/ard.2004.031476, 1755655, 15708884.
37. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):ii30-33. 1766750, 14532145.
38. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798. 10.1136/ard.61.9.793, 1754224, 12176803.
39. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006, 8:R112. 10.1186/ar2001, 1779428, 16978395.
40. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005, 44:695-696. 10.1093/rheumatology/keh562, 15705631.
41. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56:2896-2904. 10.1002/art.22808, 2435418, 17763441.